Dec. 03, 2018Topics
The MENA (Middle East and North Africa) region is a largely untapped, yet potentially hugely fruitful part of the world for the pharmaceutical industry, both as a sales region and for the establishment of manufacturing facilities.
Sep. 23, 2018Topics
The biopharmaceutical industry has grown impressively in recent years, with its global compound growth rate (CAGR) estimated to reach 8.5% between 2018-2023, outstripping traditional new chemical entity sectors. Emerging novel drugs show ...
Sep. 20, 2018Topics
Despite the favorable economic environment, the global economic risk factors have intensified against the background of record global debt and a rise in geopolitical risk. Amid growing uncertainty and regionalization, values such as trust, ...
Apr. 26, 2018News & Opinions
Mylan has joined forces with Japan’s Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar to Abbvie’s Humira (adalimumab) that has been developed by the Japanese company.
Jan. 24, 2018News & Opinions
Sandoz, the generics subsidiary of Novartis, is collaborating with Biocon, an India-based biopharmaceuticals producer, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology.
Dec. 07, 2017News & Opinions
The US Food and Drug Administration (FDA) has given the green light to Netherlands-domiciled, US-managed generic drugmaker Mylan’s Ogivri (trastuzumab-dkst) breast cancer drug, a biosimilar to the Roche blockbuster Herceptin ...
Nov. 24, 2017News & Opinions
In a suit filed in the state of Delaware, the Swiss-based Roche Holding is suing Pfizer to block the future marketing a biosimilar of its breast-cancer drug Herceptin in the US. The holding claims that the US drugs giant’s ...
Nov. 21, 2017News & Opinions
Boehringer Ingelheim has been granted its first biosimilar approval in Europe, receiving authorization to market Cyltezo for treating a variety of chronic inflammatory diseases in adults, including rheumatoid arthritis, psoriatic ...
Sep. 27, 2017Topics
Pharmaceutical companies are experiencing numerous challenges such as increasing cost pressures, declining autonomy or protocol-driven care. The reaction has to go beyond traditional instruments such as consolidation. In this new era, ...
May. 26, 2017News & Opinions
The UK’s Competition and Markets Authority (CMA) has provisionally ruled that a discount scheme operated by US drugmaker Merck for Remicade may have broken competition rules by restricting competition from cheaper biosimilar versions.
The latest information directly via newsletter.